Can cholera vaccine reduce the risk of death in colorectal cancer patients?

Share This Post

A Swedish study showed that vaccination with cholera after diagnosis of colorectal cancer can reduce the risk of colorectal cancer-related death and all-cause mortality. (Online version of Gastroenterology September 15, 2017).

This should be the first national population-based study to explore the relationship between vaccination with cholera after diagnosis of colorectal cancer and the risk of death. Previous studies have shown that the cholera vaccine may have multiple effects in regulating the body’s immune system and may also reduce the formation of colon polyps in mouse models.

The researchers believe that colorectal cancer is more common in developed countries than in developing countries. Perhaps less exposure to microbes in childhood is also associated with an increased risk of developing colorectal cancer in adulthood.

The researchers used the Swedish National Cancer Registration and Prescription Drug Registration Database to retrospectively analyze the data of 175 patients who received cholera vaccine after diagnosis of colorectal cancer from mid-2005 to 2012. As for the reason why the cholera vaccine is unknown, it may be that patients need to travel to other countries.

The analysis showed that compared with patients who were not vaccinated with cholera (525 patients), patients who received cholera vaccine after diagnosis of colorectal cancer had a 47% lower risk of colorectal cancer death and a 41% overall risk of death. This survival advantage exists in patients with different ages, genders, and stages of colorectal cancer at diagnosis.

The researchers hypothesized that the cholera vaccine may play a role in inhibiting the progression of colorectal cancer by stimulating immune cells such as CD8 positive T cells, macrophages and NK cells, and / or by affecting the expression of genes related to tumorigenesis. The researchers believe that if the results of these studies can be verified in other population-based studies or randomized clinical studies, then the use of cholera vaccine for adjuvant treatment of colorectal cancer is not impossible.

Researchers studying microbial infections and tumors have pointed out that more and more research evidence supports that microbes or their products can stimulate the body’s immune system and bring health benefits for the protection of certain types of tumors and immune-related diseases However, the improvement of sanitary conditions makes us less and less likely to obtain a healthy immune system caused by microbial exposure. A safe oral vaccine that can enhance immune function may bring us significant health benefits. 

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Best Cancer Hospitals In China
Cancer Hospitals Abroad

Best Cancer Hospitals in China 2025

  Best Cancer Hospitals in China China has become a world leader in medical innovation, especially in oncology. The nation has, over the past decade,

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer treatment in South Korea

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟